Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 12/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15680285 | 0.78 | ACHE (0.50) | ACHE | |
| SCHEMBL30474877 | 0.76 | ACHE (0.56) | CYP2C19HIF1AACHEKMT2AALDH1A1 | |
| SCHEMBL14493000 | 0.76 | ACHE (0.42) | ACHE | |
| SCHEMBL3523047 | 0.76 | ACHE (0.59) | ACHEKMT2ATSHRGFER | |
| SCHEMBL3524808 | 0.75 | ACHE (0.58) | ACHEKMT2ATSHRGFER | |
| SCHEMBL15680257 | 0.72 | ACHE (0.39) | ACHEBRD4 | |
| SCHEMBL17300606 | 0.69 | MAPT (0.39) | ALDH1A1HPGDHTTMCL1 | |
| SCHEMBL30476250 | 0.67 | PIM1 (0.50) | ACHEKMT2AALDH1A1HTT | |
| SCHEMBL3523468 | 0.65 | ACHE (0.57) | ACHEKMT2AALDH1A1 | |
| SCHEMBL3522808 | 0.64 | ACHE (0.56) | ACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174053-B2 | 2 substituted cephem compounds | GLAXO GROUP LIMITED (GB) | 2019-01-08 | — | — | US | disclosed |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20150344502-A1 | CEPHEM COMPOUND | SHIONOGI & CO., LTD. (JP) | 2015-12-03 | — | — | US | disclosed |
| US-20150344502-A1 | CEPHEM COMPOUND | SHIONOGI & CO., LTD. (JP) | 2015-12-03 | — | — | US | disclosed |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-10-22 | — | — | US | disclosed |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-10-22 | — | — | US | disclosed |
| WO-2014068388-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | CEP170, CES2, CMBL | CYP2C19 248/4885HIF1A 3653/4885ACHE 271/4885 |
| US-20150344502-A1 | CEPHEM COMPOUND | PRMT6, CEP170, NR0B1 | CYP2C19 2152/4885HIF1A 2244/4885ACHE 2049/4885 |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | CEP170, ABL1, CEPT1 | CYP2C19 695/4885HIF1A 1945/4885ACHE 2567/4885 |
| US-10174053-B2 | 2 substituted cephem compounds | CEP170, CES2, CMBL | CYP2C19 248/4885HIF1A 3653/4885ACHE 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.